Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
13.02
-0.40 (-2.98%)
Feb 21, 2025, 4:00 PM EST - Market closed
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Arcutis Biotherapeutics stock have an average target of 17, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 30.57% from the current stock price of 13.02.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 13, 2025.
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 3 | 4 |
| Buy | 1 | 1 | 1 | 0 | 1 | 1 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +45.93% | Jan 13, 2025 |
| Mizuho | Mizuho | Buy Maintains $19 → $20 | Buy | Maintains | $19 → $20 | +53.61% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +45.93% | Dec 30, 2024 |
| Needham | Needham | Strong Buy Maintains $18 → $20 | Strong Buy | Maintains | $18 → $20 | +53.61% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
189.17M
from 59.61M
Increased by 217.37%
Revenue Next Year
294.42M
from 189.17M
Increased by 55.64%
EPS This Year
-1.35
from -3.78
EPS Next Year
-0.85
from -1.35
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 198.1M | 351.8M | 567.0M | |||
| Avg | 189.2M | 294.4M | 431.6M | |||
| Low | 175.2M | 251.7M | 300.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 232.4% | 85.9% | 92.6% | |||
| Avg | 217.4% | 55.6% | 46.6% | |||
| Low | 193.9% | 33.0% | 2.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.26 | -0.55 | 0.89 | |||
| Avg | -1.35 | -0.85 | 0.05 | |||
| Low | -1.38 | -1.11 | -0.44 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.